The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)
Public ClinicalTrials.gov record NCT01569438. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Four-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy of gefapixant (AF-219/MK-7264) in female participants with moderate to severe pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) after 4 weeks of treatment.
Study identification
- NCT ID
- NCT01569438
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 107 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 13, 2012 (Actual)
- Primary completion
- May 1, 2014 (Actual)
- Completion
- May 14, 2014 (Actual)
- Last update posted
- Aug 17, 2020
2012 – 2014
United States locations
- U.S. sites
- 41
- U.S. states
- 19
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Afferent Investigative Site | Glendale | Alabama | 85306 | — |
| Afferent Investigative Site | Homewood | Alabama | 35209 | — |
| Afferent Investigative Site | Mobile | Alabama | 36608 | — |
| Afferent Investigative Site | Phoenix | Arizona | 85018 | — |
| Afferent Investigative Site | Glendora | California | 91741 | — |
| Afferent Investigative Site | Murrieta | California | 91741 | — |
| Afferent Investigative Site | San Diego | California | 92120 | — |
| Afferent Investigative Site | San Diego | California | 92123 | — |
| Afferent Investigative Site | Farmington | Connecticut | 06032 | — |
| Afferent Investigative Site | New Britain | Connecticut | 06052 | — |
| Afferent Investigative Site | Boynton Beach | Florida | 33472 | — |
| Afferent Investigative Site | Plantation | Florida | 33317 | — |
| Afferent Investigative Site | Coeur d'Alene | Idaho | 83814 | — |
| Afferent Investigative Site | Idaho Falls | Idaho | 83404 | — |
| Afferent Investigative Site | Meridian | Idaho | 83642 | — |
| Afferent Investigative Site | Shreveport | Louisiana | 71106 | — |
| Afferent Investigative Site | Annapolis | Maryland | 21401 | — |
| Afferent Investigative Site | Ann Arbor | Michigan | 48109 | — |
| Afferent Investigative Site | Grand Rapids | Michigan | 49503 | — |
| Afferent Investigative Site | Kalamazoo | Michigan | 49009 | — |
| Afferent Investigative Site | Royal Oak | Michigan | 48073 | — |
| Afferent Investigative Site | Voorhees Township | New Jersey | 08043 | — |
| Afferent Investigative Site | Albuquerque | New Mexico | 87109 | — |
| Afferent Investigative Site | Brooklyn | New York | 11215 | — |
| Afferent Investigative Site | Hyde Park | New York | 11040 | — |
| Afferent Investigative Site | Greenville | North Carolina | 27834 | — |
| Afferent Investigative Site | Salisbury | North Carolina | 28144 | — |
| Afferent Investigative Site | Winston-Salem | North Carolina | 27103 | — |
| Afferent Investigative Site | Cincinnati | Ohio | 45212 | — |
| Afferent Investigative Site | Cleveland | Ohio | 44109 | — |
| Afferent Investigative Site | Tiffin | Ohio | 43351 | — |
| Afferent Investigative Site | Zanesville | Ohio | 43701 | — |
| Afferent Investigative Site | Bala-Cynwyd | Pennsylvania | 19004 | — |
| Afferent Investigative Site | Lancaster | Pennsylvania | 17604 | — |
| Afferent Investigative Site | Myrtle Beach | South Carolina | 29572 | — |
| Afferent Investigative Site | Dallas | Texas | 75390 | — |
| Afferent Investigative Site | Fort Worth | Texas | 76104 | — |
| Afferent Investigative Site | Houston | Texas | 77062 | — |
| Afferent Investigative Site | Irving | Texas | 75062 | — |
| Afferent Investigative Site | Salt Lake City | Utah | 84124 | — |
| Afferent Investigative Site | Virginia Beach | Virginia | 23462 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01569438, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2020 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01569438 live on ClinicalTrials.gov.